As of close of business last night, Organogenesis Holdings Inc’s stock clocked out at $2.83, up 1.07% from its previous closing price of $2.80. In other words, the price has increased by $+0.0300 from its previous closing price. On the day, 5333944 shares were traded.
Ratios:
To gain a deeper understanding of ORGO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 57.01. For the most recent quarter (mrq), Quick Ratio is recorded 2.44 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 0.43 whereas as Long-Term Debt/Eq ratio is at 0.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 07, 2024, initiated with a Overweight rating and assigned the stock a target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.
BTIG Research Upgraded its Neutral to Buy on May 24, 2023, while the target price for the stock was maintained at $10.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 10 ’24 when ERANI ALBERT sold 17,972 shares for $4.28 per share. The transaction valued at 76,875 led to the insider holds 59,007,134 shares of the business.
ERANI ALBERT sold 17,972 shares of ORGO for $76,875 on Jan 10 ’24. The 10% Owner now owns 59,007,134 shares after completing the transaction at $4.28 per share. On Jan 09 ’24, another insider, ERANI ALBERT, who serves as the 10% Owner of the company, sold 197,921 shares for $4.37 each. As a result, the insider received 863,985 and left with 59,025,106 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORGO now has a Market Capitalization of 374.78M and an Enterprise Value of 390.29M. As of this moment, Organogenesis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 77.11, and their Forward P/E ratio for the next fiscal year is 33.96. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 32.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.86 while its Price-to-Book (P/B) ratio in mrq is 1.33. Its current Enterprise Value per Revenue stands at 0.90 whereas that against EBITDA is 10.83.
Stock Price History:
Over the past 52 weeks, ORGO has reached a high of $4.70, while it has fallen to a 52-week low of $1.79. The 50-Day Moving Average of the stock is 3.1669, while the 200-Day Moving Average is calculated to be 3.1259.
Shares Statistics:
It appears that ORGO traded 674.52K shares on average per day over the past three months and 996.31k shares per day over the past ten days. A total of 131.32M shares are outstanding, with a floating share count of 77.32M. Insiders hold about 41.42% of the company’s shares, while institutions hold 44.54% stake in the company. Shares short for ORGO as of Mar 15, 2024 were 8.01M with a Short Ratio of 11.88, compared to 7.47M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.07% and a Short% of Float of 26.30%.
Earnings Estimates
As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.03 for the current quarter, with a high estimate of -$0.01 and a low estimate of -$0.04, while EPS last year was -$0.02. The consensus estimate for the next quarter is $0, with high estimates of $0.01 and low estimates of -$0.01.
Analysts are recommending an EPS of between $0 and -$0.02 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0.06, with 3 analysts recommending between $0.1 and $0.
Revenue Estimates
A total of 3 analysts have provided revenue estimates for ORGO’s current fiscal year. The highest revenue estimate was $457.08M, while the lowest revenue estimate was $453.3M, resulting in an average revenue estimate of $454.69M. In the same quarter a year ago, actual revenue was $433.14M, up 5.00% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $490.38M in the next fiscal year. The high estimate is $495.5M and the low estimate is $481.33M. The average revenue growth estimate for next year is up 7.80% from the average revenue estimate for this year.
